Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...
As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with ...
News Medical on MSN2d
Study reveals immune system changes linked to schizophrenia and treatment resistanceResearchers from Singapore's National Healthcare Group (NHG)'s Institute of Mental Health (IMH) and Agency for Science, ...
Hosted on MSN2d
What Is the Difference Between Psychosis and Schizophrenia?Medically reviewed by Dakari Quimby, PhD Psychosis and schizophrenia are related but distinct mental health conditions ...
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were ...
The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.
Luna will jump on his lap and put her head against his, preventing Green from hitting his face and bringing him back to the present moment. Start the day smarter. Get all the news you need in your ...
Ingelheim, Germany Saturday, January 18, 2025, 11:00 Hrs [IST] ...
Treatment-resistant schizophrenia (TRS) is generally understood as a failure to respond to at least two trials of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback